Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma-Reference-Cited by-同舟云学术

Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma

Published:2020-10-12 Issue:12 Volume:11 Page:3419-3421
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Qiu Hai‐Bo¹

Affiliation:

1. Department of Gastric Surgery Sun Yat‐sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine Guangzhou China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13690

Reference15 articles.

1. Cancer statistics, 2020

2. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?

3. Global Cancer Incidence and Mortality Rates and Trends—An Update

4. National trend of gastric cancer mortality in China (2003‐2015): A population‐based study;Gao K;Cancer Commun,2019

5. SEOM clinical guideline for the diagnosis and treatment of esophageal cancer (2016);Martin‐Richard M;Clin Transl Oncol,2016

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and tolerability of programmed cell death protein-1 inhibitor + chemotherapy compared to chemotherapy for upper gastrointestinal tract cancers;World Journal of Gastrointestinal Oncology;2024-04-15

2. PD-L1 aptamer-functionalized degradable hafnium oxide nanoparticles for near infrared-II diagnostic imaging and radiosensitization;Frontiers in Bioengineering and Biotechnology;2023-06-07

3. Comparison of McKeown Minimally Invasive Esophagectomy vs sweet esophagectomy for esophageal squamous cell carcinoma: A retrospective study;Frontiers in Oncology;2022-12-19

4. From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades;Frontiers in Immunology;2022-08-03